fda warning letters compounded semaglutide october 2025 GLP-1s: Why doctors worry and the is cracking down FDA warns against compounded GLP-1

[9] [10] In individuals with compromised cardiac function, this mechanism may pose additional considerations that require specialist evaluation

How Does GLP-1 Help You Lose Weight

Concerns about the potential association between certain diabetes medications and cardiovascular disease meant that in 2010 the FDA approved liraglutide on condition that Novo Nordisk conduct a post-marketing study to evaluate the drug's effect on the incidence of major cardiovascular events (Nielsen, DeChiaro, Goldman)

The status quo The World Health Organization classified obesity as a disease in 1948

Assess risk stratification of member population

The drugs novelty lies in the fact that it includes a glucagon receptor agonist, which most other GLP-1 therapies do not have